Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Overview of Hematopoiesis

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ENDOCRINE DISTURBANCES IN PARASELLAR MENINGIOMAS AND THE EFFECT OF TRANSSPHENOIDAL DECOMPRESSION OPERATIONS.

Acta endocrinologica (Bucharest, Romania : 2005)·2026

Same author

Editorial Expression of Concern: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.

Oncogene·2024

Same author

The KMT2A recombinome of acute leukemias in 2023.

Leukemia·2023

Same author

Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.

Immunobiology·2021

Same author

Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease.

Immunological investigations·2019

Same author

The MLL recombinome of acute leukemias in 2017.

Leukemia·2017

Search research articles

Related Experiment Video

Updated: May 23, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

MiR-125 in normal and malignant hematopoiesis.

L Shaham¹, V Binder, N Gefen

¹Department of Pediatric Hemato-Oncology, Functional Genomics and Childhood Leukemia Research, Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

|March 30, 2012

Summary

MicroRNA 125 (miR-125) is crucial in hematopoietic stem cells (HSCs), promoting survival and self-renewal. Dysregulated miR-125 expression in leukemia drives oncogenesis by blocking cell differentiation and promoting apoptosis resistance.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 23, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Area of Science:

Molecular Biology
Genetics
Hematology

Background:

MicroRNA 125 (miR-125) is a conserved non-coding RNA with three human homologs.
miR-125 plays a significant role in regulating cellular processes.

Purpose of the Study:

To review the role of miR-125 in normal and malignant hematopoietic cells.
To elucidate the function of miR-125 in hematopoiesis and leukemia.

Main Methods:

Review of recent research findings.
Analysis of miR-125 expression patterns in various hematopoietic cell types.
Examination of mouse models demonstrating miR-125's oncogenic role.

Main Results:

High miR-125 expression in hematopoietic stem cells (HSCs) supports self-renewal and survival.
Aberrant miR-125 expression in leukemias confers resistance to apoptosis and inhibits differentiation.
Mouse models confirm a direct oncogenic function of miR-125 in the hematopoietic system.

Conclusions:

miR-125 is a key regulator in both normal hematopoiesis and leukemogenesis.
Targeting miR-125 may offer therapeutic strategies for hematologic malignancies.